379 related articles for article (PubMed ID: 25845879)
1. Ibuprofen potentiates the in vivo antifungal activity of fluconazole against Candida albicans murine infection.
Costa-de-Oliveira S; Miranda IM; Silva-Dias A; Silva AP; Rodrigues AG; Pina-Vaz C
Antimicrob Agents Chemother; 2015 Jul; 59(7):4289-92. PubMed ID: 25845879
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
[TBL] [Abstract][Full Text] [Related]
3. Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction.
Shen H; An MM; Wang de J; Xu Z; Zhang JD; Gao PH; Cao YY; Cao YB; Jiang YY
Biol Pharm Bull; 2007 Jan; 30(1):68-73. PubMed ID: 17202662
[TBL] [Abstract][Full Text] [Related]
4. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
[TBL] [Abstract][Full Text] [Related]
5. Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans.
Arai R; Sugita T; Nishikawa A
Mycoses; 2005 Jan; 48(1):38-41. PubMed ID: 15679664
[TBL] [Abstract][Full Text] [Related]
6. Ibuprofen reverts antifungal resistance on Candida albicans showing overexpression of CDR genes.
Ricardo E; Costa-de-Oliveira S; Dias AS; Guerra J; Rodrigues AG; Pina-Vaz C
FEMS Yeast Res; 2009 Jun; 9(4):618-25. PubMed ID: 19416368
[TBL] [Abstract][Full Text] [Related]
7. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.
Quan H; Cao YY; Xu Z; Zhao JX; Gao PH; Qin XF; Jiang YY
Antimicrob Agents Chemother; 2006 Mar; 50(3):1096-9. PubMed ID: 16495278
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
Khan MA; Khan A; Owais M
FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598
[TBL] [Abstract][Full Text] [Related]
9. An Azole-Tolerant Endosomal Trafficking Mutant of Candida albicans Is Susceptible to Azole Treatment in a Mouse Model of Vaginal Candidiasis.
Peters BM; Luna-Tapia A; Tournu H; Rybak JM; Rogers PD; Palmer GE
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348159
[TBL] [Abstract][Full Text] [Related]
10. Potent drugs that attenuate anti-Candida albicans activity of fluconazole and their possible mechanisms of action.
Urai M; Kaneko Y; Niki M; Inoue M; Tanabe K; Umeyama T; Fukazawa H; Ohno H; Miyazaki Y
J Infect Chemother; 2014 Oct; 20(10):612-5. PubMed ID: 25009090
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of aminocandin in the treatment of immunocompetent mice with haematogenously disseminated fluconazole-resistant candidiasis.
Ghannoum MA; Kim HG; Long L
J Antimicrob Chemother; 2007 Mar; 59(3):556-9. PubMed ID: 17242032
[TBL] [Abstract][Full Text] [Related]
12. Rep1p negatively regulating MDR1 efflux pump involved in drug resistance in Candida albicans.
Chen CG; Yang YL; Tseng KY; Shih HI; Liou CH; Lin CC; Lo HJ
Fungal Genet Biol; 2009 Sep; 46(9):714-20. PubMed ID: 19527793
[TBL] [Abstract][Full Text] [Related]
13. Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-Resistant
Xu J; Liu R; Sun F; An L; Shang Z; Kong L; Yang M
Front Cell Infect Microbiol; 2019; 9():211. PubMed ID: 31281800
[TBL] [Abstract][Full Text] [Related]
14. Mutation of G234 amino acid residue in candida albicans drug-resistance-related protein Rta2p is associated with fluconazole resistance and dihydrosphingosine transport.
Zhang SQ; Miao Q; Li LP; Zhang LL; Yan L; Jia Y; Cao YB; Jiang YY
Virulence; 2015; 6(6):599-607. PubMed ID: 26220356
[TBL] [Abstract][Full Text] [Related]
15. Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients.
Siikala E; Rautemaa R; Richardson M; Saxen H; Bowyer P; Sanglard D
J Antimicrob Chemother; 2010 Dec; 65(12):2505-13. PubMed ID: 20876623
[TBL] [Abstract][Full Text] [Related]
16. Fluconazole resistance in Candida albicans: a review of mechanisms.
Casalinuovo IA; Di Francesco P; Garaci E
Eur Rev Med Pharmacol Sci; 2004; 8(2):69-77. PubMed ID: 15267120
[TBL] [Abstract][Full Text] [Related]
17. The in vitro and in vivo efficacy of fluconazole in combination with farnesol against Candida albicans isolates using a murine vulvovaginitis model.
Bozó A; Domán M; Majoros L; Kardos G; Varga I; Kovács R
J Microbiol; 2016 Nov; 54(11):753-760. PubMed ID: 27796932
[TBL] [Abstract][Full Text] [Related]
18. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance.
Miyazaki T; Miyazaki Y; Izumikawa K; Kakeya H; Miyakoshi S; Bennett JE; Kohno S
Antimicrob Agents Chemother; 2006 Feb; 50(2):580-6. PubMed ID: 16436713
[TBL] [Abstract][Full Text] [Related]
19. In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling.
Andes D; Lepak A; Nett J; Lincoln L; Marchillo K
Antimicrob Agents Chemother; 2006 Jul; 50(7):2384-94. PubMed ID: 16801416
[TBL] [Abstract][Full Text] [Related]
20. A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model.
Hayama K; Ishibashi H; Ishijima SA; Niimi K; Tansho S; Ono Y; Monk BC; Holmes AR; Harding DR; Cannon RD; Abe S
FEMS Microbiol Lett; 2012 Mar; 328(2):130-7. PubMed ID: 22211961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
